Article
Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Oncotarget - 3 Nov 2015
Prenen Hans, Smeets Dominiek, Mazzone Massimiliano, Lambrechts Diether, Sagaert Xavier, Sciot Raf, Debiec-Rychter Maria
Abstract excerpt
Hepatic angiosarcoma is a rare and aggressive vascular neoplasm. Pathogenic driver mutations are largely unknown. We present the case of a patient with recurrent hepatic angiosarcoma, who initially showed good response to sunitinib, followed by progression. Using comprehensive molecular techniques, we explored the potential mechanisms of resistance. By low-read-depth whole-genome sequencing, the comparison of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.